

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM, ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

CLINICAL COMPUTING PLC

8 February 2017

Clinical Computing plc (the “Company”), the international developer of EMR solutions for the global kidney therapeutics market, announces that it has decided to conduct a review of various strategic options open to the Company to maximise value for shareholders, which could include a sale of the Company.

Whilst the Board believes that the Company has a secure future as an independent business, the Board has taken this decision to seek to unlock value for shareholders whilst safeguarding the interests of all stakeholders.

The Board has appointed ICON Corporate Finance Limited as financial advisor for the purposes of the strategic review.

The Takeover Panel (the “Panel”) has agreed that any discussions with third parties may be conducted with the framework set out in Note 2 on Rule 2.6 of the Takeover Code (the “Code”). The Panel has granted a dispensation from the requirements of Rules 2.4 (a), 2.4 (b) and 2.6 (a) of the Code such that any interested party will not be required to be publicly identified as a result of this announcement (subject to note 3 to Rule 2.2 of the Code) and will not be subject to the 28 day deadline referred to in Rule 2.6 (a), for so long as it is participating in discussions with the Company.

Following this announcement, the Company is now considered to be in an “offer period” as defined in the Code, and the dealing disclosure requirements listed below will apply.

The Company will make a further announcement when appropriate.

In accordance with Rule 2.10 of the Code, the Company confirms it has 127,516,247 ordinary shares of 1p each in issue. The Company’s shares are not listed on a recognised stock exchange but are part of the matching service provided by Britdaq.

Enquiries

For further information, please see www.ccl.com or contact:

Clinical Computing Plc
Sanjay Gandhi, Chief Executive
01473 694778

ICON Corporate Finance
Simon Moynagh
0207 152 6375

About Clinical Computing Plc

The Company is a leading provider of internet based medical records for the management of chronic kidney disease.

The Company was an early innovator of clinical databases and has evolved into a point of care electronic medical record specializing in clinical analytics and using information to improve patient care and business operations. Our solutions help our customers focus on:

- Improving patient care
- Improving operational performance
- Meeting regulatory reporting requirements

The Company has become an international organisation delivering leading clinical information solutions on a global basis and has ISO13485 accreditation.

Publication on Website

A copy of this announcement will be made available at www.ccl.com no later than 12:00 noon (London time) on 9 February 2017 (being the business day following the date of this announcement) in accordance with Rule 26.1 of the Code. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

ICON Corporate Finance Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for Clinical Computing plc (as financial adviser) and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than for Clinical Computing plc for providing the protections afforded to clients of ICON Corporate Finance Limited nor for providing advice in relation to the matters referred to in this announcement.

The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.